T2 Biosystems, Inc., a leading provider of rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is set to release its financial results for the first quarter of 2024 on May 6, 2024, after the market closes. The company will also provide business updates during this time. A conference call hosted by company management will begin at 4:30 p.m. Eastern Time on the same day.
Investors who wish to listen to the conference call can access a live and archived webcast of the event at www.t2biosystems.com, specifically on the Investors page in the Events & Presentations section. To participate in the call, dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with the passcode 160751 approximately ten to five minutes before the start time.
T2 Biosystems is dedicated to improving patient care and reducing healthcare costs by enabling clinicians to treat patients more efficiently. The company’s product lineup includes the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, all of which leverage proprietary T2 Magnetic Resonance (T2MR) technology. Additionally, T2 Biosystems has a pipeline of upcoming products such as U.S.-based T2Resistance Panel testing for Candida albicans and Candida krusei/Candida parasilosis complex; Candida auris testing; and Lyme disease testing using proprietary antigen detection technology (ADT). For more information about T
Jan Leike, a machine learning researcher and co-leader of ‘superalignment’ at OpenAI, announced his departure…
The city of Kyle, Texas recently attempted to break the world record for the largest…
In the first game of the 1A baseball regional, Garrett Maunu pitched exceptionally well, throwing…
In a recent meeting, Jyoti Amge, the world’s shortest woman, was lifted effortlessly by The…
Business Insider has recently analyzed the total compensation of the CEOs of the “Magnificent Seven”…
Jan Leike, a renowned machine learning researcher, has recently announced his departure from OpenAI. In…